Inhaled prazosin in asthma.

AUTOR(ES)

Barnes, P J

RESUMO

Prazosin, a potent and selective alpha-adrenergic antagonist, was given by inhalation to nine asthmatic subjects aged 25-48 years (six with positive skin tests). Prazosin 0.5 mg, salbutamol 1 mg, or placebo were given by nebuliser in randomised double-blind fashion on separate days. Although all subjects showed a significant increase in FEV1, vital capacity, and maximum expiratory flow at 70% of total lung capacity after salbutamol, there was no significant difference between prazosin and placebo. This suggests that alpha-adrenergic receptors are not important in the control of bronchial tone in asthma. The weak bronchodilatation ascribed to alpha-antagonists in previous studies could be explained by other pharmacological actions of the drugs used.

Documentos Relacionados

• Prazosin in the treatment of chronic asthma.
• Optimizing inhaled drug delivery in patients with asthma.
• Use of inhaled corticosteroids in patients with mild asthma.
• Inhaled frusemide and exercise-induced bronchoconstriction in children with asthma.
• Comparison of inhaled and intravenous terbutaline in acute severe asthma.